Jeff Walsh, nChroma CEO
December 11, 2024 07:00 AM EST
Financing
Deals
Cell/Gene Tx

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

Andrew Dunn

Senior Biopharma Correspondent

What start­ed as two CEOs eat­ing tacos and talk­ing biotech led to a merg­er and a new com­pa­ny.

The epi­ge­net­ic edit­ing start­up Chro­ma Med­i­cine and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times